The Medicare Advantage Quality Bonus Program is set to cost taxpayers over $13 billion in 2026, a figure that’s not just staggering but deeply revealing about the complexities of healthcare policy. Personally, I think this program, while well-intentioned, is a prime example of how good ideas can get tangled in bureaucracy and unintended consequences. Let me break it down for you.
The Promise and the Pitfalls
The program, part of the Affordable Care Act, aims to reward Medicare Advantage plans with higher star ratings by increasing their payments. On the surface, it’s a win-win: incentivize better quality care and give consumers more options. But here’s where it gets tricky. The star ratings, which determine eligibility for these bonuses, are based on about 40 different measures. Sounds thorough, right? Well, critics argue that these measures are overly complex, don’t account for social risk factors, and are applied at the contract level rather than the plan level. This means that plans within the same contract might offer vastly different benefits, but they’re all judged by the same star rating. What this really suggests is that the system might be rewarding the wrong things—or at least not rewarding the right things in the right way.
The Money Trail
What makes this particularly fascinating is how the money flows. UnitedHealth Group, for instance, enrolls 26% of Medicare Advantage beneficiaries but is expected to receive 29% of the bonus payments in 2026. Meanwhile, Humana, with 20% of enrollees, gets just 11% of the bonus funds. Why the disparity? It boils down to star ratings. Humana’s ratings took a hit in 2025, and they’ve even sued CMS over it. This raises a deeper question: Are these ratings truly a fair measure of quality, or are they just another battleground for insurers to game the system?
The Hidden Costs
Here’s a detail that I find especially interesting: the program’s cost has quadrupled since 2015, even as Medicare faces growing fiscal pressures. In 2026, it’s projected to account for 2.3% of total Medicare Advantage payments. But that’s just the tip of the iceberg. The program exacerbates other issues, like higher coding intensity and favorable selection, which together add $76 billion to Medicare spending in 2026. If you take a step back and think about it, this program isn’t just expensive—it’s potentially unsustainable.
The Winners and Losers
One thing that immediately stands out is how unevenly the benefits are distributed. Employer- and union-sponsored plans, which account for 16% of Medicare Advantage enrollees, receive 20% of the bonus funds. Their average payment increase per enrollee is $466, compared to just $318 for special needs plans. What many people don’t realize is that special needs plans serve some of the most vulnerable populations, including dual-eligible individuals. Lower star ratings for these plans suggest they might not be meeting their needs effectively, but the data gaps make it hard to say for sure. This disparity raises questions about equity in healthcare—are we inadvertently favoring certain groups over others?
The Future of the Program
Critiques of the program have led to calls for reform or even elimination. The Congressional Budget Office estimated in 2018 that axing the program could save nearly $100 billion over a decade. Given the surge in Medicare Advantage enrollment since then, the savings could be even higher. But here’s the catch: eliminating or reforming the program could impact plan quality and the availability of supplemental benefits. It’s a classic policy dilemma—how do you balance cost with quality?
My Take
In my opinion, the Quality Bonus Program is a classic case of good intentions meeting bad execution. It’s trying to solve a real problem—improving healthcare quality—but the current system is too flawed to deliver on that promise. The star ratings need to be simplified, more transparent, and better aligned with patient outcomes. Until then, we’re throwing billions at a program that might be doing more harm than good. What this really suggests is that we need a fundamental rethink of how we measure and reward quality in healthcare.
The $13 billion price tag isn’t just a number—it’s a symptom of a larger issue. As we debate the future of Medicare, this program should be at the center of the conversation. Because if we don’t get this right, we’re not just wasting money—we’re missing an opportunity to truly improve care for millions of Americans.
